London, April 12th, 2022 – NanoMab Technology Limited, a privately held biopharmaceutical company focussing on cancer precision therapies is delighted to announce that over the course of the last two quarters it has taken the next steps forward in its commitment to developing next generation pharmaceuticals by forming exclusive licensing agreements with Radiopharm Theranostics (ASX: RAD) and Full Life Technologies (HK) Ltd.
The agreements grant RAD full rights to develop three of NanoMab’s single-domain antibody assets: NM-02, NM-03, and NM-04; respectively targeting HER-2 (breast cancer), TROP-2 (triple negative breast cancer), and PTK7 (multiple solid tumours) biomarkers. RAD is an ASX-listed company led by a strong global team with world-class experience, who aim to develop radiopharmaceutical products for both diagnostic and therapeutic uses in areas of high unmet medical needs. RAD is the latest venture of Australian bioentrepreneur, Paul Hopper, who is behind numerous successful companies developing oncology drugs.
Additionally, an agreement issuing the full IP right to develop NM-05 (sdAb targeting FAP) has been established with Full-Life Technologies (HK) Ltd. Full-life is a global nuclear health company seeking to tackle two core issues experienced in the radiopharmaceuticals sector; the ability to produce primarily alpha- and beta- medical radioisotopes in quantity, and the development of an innovative translational research platform for Targeted-Radiotherapy.
NanoMab believes these exclusive licensing agreements have formalised the strategic collaborations between the respective parties, which will speed up the development and commercialisation of our unique platform of immuno-oncology theranostic drugs to aid patients in the battle against aggressive cancers.
For more information email: firstname.lastname@example.org
NanoMab Technology Limited is a privately held biopharmaceutical company focusing on cancer precision therapies via the development of radiopharmaceuticals. Our goal is to develop a pipeline of theranostics with our proprietary camelid antibody platform to address the unmet medical need for cancer patients across the world. www.nano-mab.com